Acumen Pharmaceuticals(US:ABOS) Newsfilter·2024-07-11 12:00Core Insights - Acumen Pharmaceuticals is set to present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer's Association International Conference (AAIC®) 2024, highlighting its focus on Alzheimer's disease treatment [1][2] Company Overview - Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing sabirnetug (ACU193), a humanized monoclonal antibody targeting toxic soluble amyloid beta oligomers (AβOs) for Alzheimer's disease [3][6] - The company has received Fast Track designation from the U.S. FDA for sabirnetug in treating early Alzheimer's disease [3] Product Details - Sabirnetug is the first humanized monoclonal antibody to selectively engage AβOs in patients with early symptomatic Alzheimer's disease, aiming to address synaptic dysfunction and neurodegeneration [2][3] - The INTERCEPT-AD study, completed in 2023, involved 65 participants and evaluated the safety, tolerability, and clinical proof of mechanism of sabirnetug [4][5] Upcoming Conference Presentations - Acumen will present several posters at the AAIC 2024, including: - A gender analysis of trial participants [2] - Development of a sensitive immunoassay for detecting sabirnetug in cerebrospinal fluid [2] - Analysis of synaptic biomarkers associated with sabirnetug [2] - Insights into patient experiences and expectations for treatment [2] Clinical Trial Information - The INTERCEPT-AD study was a multi-center, randomized, double-blind, placebo-controlled trial designed to assess the pharmacokinetics and target engagement of sabirnetug [4][5] - The study included both single-ascending-dose and multiple-ascending-dose cohorts [5] Future Directions - Acumen is advancing sabirnetug into a Phase 2 clinical trial, ALTITUDE-AD, following positive results from the Phase 1 trial [6]